METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAF V600/k mutant advanced or metastatic melanoma (MM)

Caroline Robert; Keith T. Flaherty; Peter Hersey; Paul D. Nathan; Claus Garbe; Mohammed M. Milhem; Lev V. Demidov; Jessica C. Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M. G. Larkin; Jochen Utikal; Michelle Casey; Laurie Jill Sherman; Wendy A. Crist; Frank S. Wu; Kiran Patel; Dirk Schadendorf

doi:10.1200/jco.2012.30.15_suppl.lba8509

Back

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAF V600/k mutant advanced or metastatic melanoma (MM)

Abstract

Peer reviewed

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAF V600/k mutant advanced or metastatic melanoma (MM)

Caroline Robert, Keith T. Flaherty, Peter Hersey, Paul D. Nathan, Claus Garbe, Mohammed M. Milhem, Lev V. Demidov, Jessica C. Hassel, Piotr Rutkowski, Peter Mohr, …

Journal of clinical oncology, Vol.30(15_suppl), pp.LBA8509-LBA8509

05/20/2012

DOI: 10.1200/jco.2012.30.15_suppl.lba8509

View Online

Abstract

LBA8509 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Details

Title: Subtitle: METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAF V600/k mutant advanced or metastatic melanoma (MM)
Creators: Caroline Robert - Institut Gustave Roussy
Keith T. Flaherty - Massachusetts General Hospital
Peter Hersey - Melanoma Institute Australia
Paul D. Nathan - Mount Vernon Cancer Centre
Claus Garbe - University of Tübingen
Mohammed M. Milhem - University of Iowa
Lev V. Demidov - Russian Academy of Sciences
Jessica C. Hassel - National Center for Tumor Diseases
Piotr Rutkowski - The Maria Sklodowska-Curie National Research Institute of Oncology
Peter Mohr - Elbe Kliniken Stade-Buxtehude
Reinhard Dummer - University Hospital of Zurich
Uwe Trefzer - Charité - Universitätsmedizin Berlin
James M. G. Larkin - Royal Marsden Hospital
Jochen Utikal - German Cancer Research Center
Michelle Casey - GlaxoSmithKline, Collegeville, PA
Laurie Jill Sherman - GlaxoSmithKline, Collegeville, PA
Wendy A. Crist - GlaxoSmithKline, Collegeville, PA
Frank S. Wu - GlaxoSmithKline, Collegeville, PA
Kiran Patel - GlaxoSmithKline, Collegeville, PA
Dirk Schadendorf - Essen University Hospital
Resource Type: Abstract
Publication Details: Journal of clinical oncology, Vol.30(15_suppl), pp.LBA8509-LBA8509
DOI: 10.1200/jco.2012.30.15_suppl.lba8509
ISSN: 0732-183X
eISSN: 1527-7755
Language: English
Date published: 05/20/2012
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984363304402771

Metrics

5 Record Views